



C

	Synergy Model	
	A549	Flo1
Vorinostat + VS-4718	Bliss: 5.9, ZIP: 6.1	Bliss: 6.5, ZIP: 6.7
Panobinostat + VS-4718	Bliss: 5.7, ZIP: 6.1	Bliss: 8.0, ZIP: 8.1



Supplementary Figure S4. Analysis of HDAC and FAK inhibition in A549 and Flo1 cell lines. **A**, Example Bliss synergy map of A549 cell viability. **B**, Example Bliss synergy map of Flo1 cell viability. For **A** and **B**, data are mean cell viabilities normalized to DMSO from 3-day drug-treated cells as displayed in Fig. 3C, ($n = 3$ independent experiments). **C**, Summary table of synergy models for HDAC and FAK inhibitor combinations. **D**, Primary dermal fibroblast (mean) viability after treatment with VS-4718 in combination with vorinostat or panobinostat for 3 days. ($n = 3$ independent experiments). **E**, Reverse phase protein array (RPPA) pathway analysis. Flo1 lysates were subjected to RPPA analysis using 120 antibodies against canonical cancer cell signaling pathways. Selected antibodies were hierarchically clustered and displayed as a heatmap. VS-4718, 500 nM, vorinostat, 5 μ M and panobinostat, 7.5 nM. Mean relative fluorescence value of three technical replicates is shown converted to a Z-score.